Mersana Therapeutics Inc
Mersana Therapeutics Inc logo
MRSN

Mersana Therapeutics Inc (MRSN)

$7.010.14%

Live
  • $

1D

1W

1M

1Y

3Y

5Y

Key Stats

$6.91
Day's Range
$7.205
$2.68
52-Week Range
$8.34
1 month return26.49%
3 month return5.72%
1 year return56.0%
5 year return51.45%

Analyst Recommendation

based on 13 analysts ratings

Buy
84%
Buy
15%
Hold
0%
Sell

Based on 13 Wall street analysts offering stock ratings for Mersana Therapeutics Inc(by analysts ranked 0 to 5 stars)

Analyst Forecast

What analysts predicted

Upside of 140.09%

Current

$7.01

Target

$16.83

Recommendation Trend

Based on 13 analyst

Current1M Ago3M Ago
Buy
11
6
10
Hold
2
1
2
Sell
0
0
0
Consensus
BUY
BUY
BUY

Company Financials

  • Annual
  • Quarterly

Highlights

Market Capitalization700.4M
Book Value$0.92
Dividend Share0.0
Dividend Yield0.0%
Earnings Per Share (EPS)-2.49
PEG Ratio0.0
Wall Street Target Price16.83

Valuation

Trailing PE0.0
Forward PE0.0
Price/Book (mrq)7.14
Enterprise Value391.3M
Enterprise Value/Revenue32.87
Enterprise Value/Ebitda-1.92

Technicals

Beta1.72
50 Day MA6.29
200 Day MA5.81

Institutional Holdings

Orbimed Advisors, LLC

9.03%

Bain Capital Life Sciences Investors, LLC

8.68%

venBio Select Advisor LLC

7.57%

BlackRock Inc

7.1%

Vanguard Group Inc

4.39%

Bellevue Group AG

4.09%

Company Information

Mersana Therapeutics is a clinical-stage biopharmaceutical company using its differentiated and proprietary ADC platforms to rapidly develop novel ADCs with optimal efficacy, safety and tolerability to meaningfully improve the lives of people fighting cancer. Mersana's lead product candidate, upifitamab rilsodotin (UpRi), is a Dolaflexin ADC targeting NaPi2b and is in the expansion portion of a Phase 1 proof-of-concept clinical study in patients with ovarian cancer and NSCLC adenocarcinoma. XMT-1592, Mersana's second ADC product candidate targeting NaPi2b-expressing tumors, was created using Mersana's customizable and homogeneous Dolasynthen platform and is in the dose escalation portion of a Phase 1 proof-of-concept clinical study. The Company's early-stage programs include XMT-1660, a Dolasynthen ADC targeting B7-H4, as well as XMT-2056, a STING-agonist ADC developed using the Company's Immunosynthen platform. In addition, multiple partners are using Mersana's Dolaflexin platform to advance their ADC pipelines.
OrganizationMersana Therapeutics Inc
Employees169
CEOMs. Anna Protopapas M.B.A.
IndustryHealth Technology

Discover more

Frequently Asked Questions

What is Mersana Therapeutics Inc share price today?

Can Indians buy Mersana Therapeutics Inc shares?

How can I buy Mersana Therapeutics Inc shares from India?

Can Fractional shares of Mersana Therapeutics Inc be purchased?

What are the documents required to start investing in Mersana Therapeutics Inc stocks?

What are today’s High and Low prices of Mersana Therapeutics Inc?

What are today’s traded volumes of Mersana Therapeutics Inc?

What is today’s market capitalisation of Mersana Therapeutics Inc?

What is the 52 Week High and Low Range of Mersana Therapeutics Inc?

How much percentage Mersana Therapeutics Inc is down from its 52 Week High?

How much percentage Mersana Therapeutics Inc is up from its 52 Week low?

What are the historical returns of Mersana Therapeutics Inc?

Who is the Chief Executive Officer (CEO) of Mersana Therapeutics Inc?

Trading and brokerage services provided by

Banking and Remittance services provided by

Technology services provided by : Finzoomers Services Private Limited

Disclaimer: These services are not for exchange traded products.The securities quoted are exemplary and not recommendatory. Please be informed that US Stocks are not exchange traded funds in India and Finzoomers Services Private Limited acts in the capacity of facilitator of this product. All disputes with respect to the transaction facilitation services, would not have access to Indian Exchange investor redressal forum or Arbitration mechanism in India. T&C apply*